Syndax Pharmaceuticals, Inc. (SNDX) News
Follow Syndax Pharmaceuticals, Inc. (SNDX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 25 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
SNDX Reports Fiscal Q3 Profit and EPS Figures
SNDX reported fiscal 2026 third-quarter profit attributable to shareholders of -1.415亿美元, up 34.93% year over year. Basic earnings per share was -1.59美元.
EQUITY | Nov 03, 2026, 05:41 AM UTC
M
Syndax Pharmaceuticals Posts Q3 Net Loss of $0.55
Syndax reported a Q3 net loss of $0.55, versus FactSet's estimate of a $0.50 loss.
EQUITY | Nov 02, 2026, 10:37 PM UTC
M
Syndax Q3 Revenue Reaches $83.298 Million
Syndax Pharmaceuticals reported Q3 revenue of USD 83.298 million versus the IBES estimate of USD 81.8 million.
EQUITY | Nov 02, 2026, 09:55 PM UTC
M
Syndax Pharmaceuticals Reports Q3 EPS USD -0.55 vs IBES Estimate USD -0.49
Syndax Pharmaceuticals reported Q3 EPS of USD -0.55 versus the IBES estimate of USD -0.49.
EARNINGS | Nov 02, 2026, 09:54 PM UTC
L
Syndax Forecasts 2026 R&D and SG&A Expenses at $400 Million
Syndax forecasts 2026 R&D and SG&A expenses of $400 million, excluding $50 million in stock option expense.
EARNINGS | Nov 02, 2026, 09:47 PM UTC
M
Syndax Reports Q3 Revenue of $83.3 Million
Syndax Pharmaceuticals reported Q3 revenue of $83.3 million, versus a FactSet estimate of $81.4 million.
EQUITY | Nov 02, 2026, 09:14 PM UTC
M
Syndax Pharmaceuticals Reports $49.4M Third-Quarter Loss
EQUITY | Nov 02, 2026, 09:11 PM UTC
M
Syndax Pharmaceuticals Q3 Revenue Rises 82% on Cancer Drug Sales
EQUITY | Nov 02, 2026, 09:09 PM UTC
M
Syndax Pharmaceuticals reports Q3 net income below estimate
Syndax Pharmaceuticals reported Q3 net income of USD -49.433 million, versus an IBES estimate of USD -45.2 million.
EARNINGS | Nov 02, 2026, 09:03 PM UTC
M
Syndax Reports Third-Quarter 2026 Financial Results and Business Update
Syndax reported total revenue of $83.3 million in 3Q26, up 82% year over year.
EQUITY | Nov 02, 2026, 09:01 PM UTC
M
Syndax to Report Third-Quarter 2026 Results on November 2
Syndax plans to announce its third-quarter 2026 financial results and host a conference call and webcast on November 2, 2026.
EQUITY | Oct 26, 2026, 11:01 AM UTC
M
Syndax Shares Fall 17% After Disappointing Lung Disease Trial Results
Syndax Pharmaceuticals shares fell 17% to $13.80 after the drugmaker reported disappointing trial results for a lung disease treatment, setting back efforts to expand the market for an approved medicine.
EQUITY | Oct 13, 2026, 03:24 PM UTC
M
Syndax shares slump 16% after axatilimab misses mid-stage trial goal
Syndax Pharmaceuticals said its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis. Shares fell 15% after hours on Monday.
EQUITY | Oct 12, 2026, 10:12 PM UTC
M
Syndax Pulmonary Fibrosis Drug Trial Misses Primary Endpoint
Syndax says its trial of axatilimab for idiopathic pulmonary fibrosis missed its primary endpoint. The company does not plan further development of the drug for this disease.
EQUITY | Oct 12, 2026, 08:38 PM UTC
L
SNDX: Key phase II readouts and expanding maintenance therapy drive growth and pipeline momentum
Two commercial drugs are driving strong revenue growth, with recurring post-transplant maintenance therapy emerging as a key driver. Multiple pivotal and phase II readouts are expected in the next year, including for IPF
EARNINGS | Sep 15, 2026, 03:24 PM UTC
L
SNDX: Strong commercial growth and pivotal clinical catalysts set the stage for major pipeline advances
Two commercial assets are driving strong revenue growth, with real-world data supporting expanded use and maintenance therapy as a key growth driver. Multiple near-term clinical readouts, including for IPF and cGVHD, and
NEWS | Sep 15, 2026, 02:53 PM UTC
L
SNDX: Dominant AML market share, advancing pivotal trials, and expanding pipeline in oncology and fibrosis
Strong commercial momentum continues with 85%+ AML market share and robust revenue growth. Multiple pivotal and innovative studies are advancing in AML, IPF, and GVHD, with key data readouts expected by year-end. Early-s
EQUITY | Sep 10, 2026, 02:21 PM UTC
L
SNDX: Dominant AML market share, global pivotal trials, and major data readouts expected in Q4 and at ASH
Strong commercial momentum continues with 85%+ market share in key AML segments and robust growth. Two pivotal phase III AML studies are enrolling globally, with additional innovation in IPF, GVHD, and novel oncology pro
EQUITY | Sep 10, 2026, 01:41 PM UTC
L
Syndax Pharmaceuticals grants inducement awards for up to 175,000 shares
Syndax Pharmaceuticals announced inducement grants under NASDAQ Listing Rule 5635(c)(4) on Sept. 1, 2026, to purchase up to 175,000 shares of common stock.
EQUITY | Sep 04, 2026, 08:07 PM UTC
L
Syndax Pharmaceuticals reports inducement grants under NASDAQ Rule 5635(c)(4)
Syndax Pharmaceuticals (SNDX) reports inducement grants under NASDAQ Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:01 PM UTC
L
Syndax management to participate in September investor conferences
Syndax Pharmaceuticals said CEO Michael A. Metzger and members of the management team will participate in September investor conferences.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
Syndax to participate in September investor conferences
Syndax says it will participate in September investor conferences.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
SNDX - Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
SNDX - Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 04, 2026, 08:02 PM UTC
L
SNDX Maintain Buy, $31 PT following R&D day @ GUGG
SNDX Maintain Buy, $31 PT following R&D day @ GUGG
EQUITY | Jul 15, 2026, 12:56 PM UTC
L
Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing
() -- Michael A Metzger, Director, Chief Executive Officer, on July 08, 2026, sold 32,375 shares in Syndax Pharmaceuticals (SNDX) for $784,776. Following the Form 4 filing with the SEC, Metzger has control over a total o
REGULATION | Jul 09, 2026, 08:57 PM UTC